Bioavailability of regular and controlled-release chlorpheniramine products.
The bioavailability of chlorpheniramine regular-release versus controlled-release products was compared using 15 human subjects. The dosage forms evaluated were an 8-mg barrier coated-bead capsule, an 8-mg repeat action tablet, two 4-mg tablets, and 4- and 8-mg syrups. Single doses of each product were administered orally in a 5-way crossover study, plasma samples were collected at specific time intervals, and chlorpheniramine levels assayed by HPLC. Pharmacokinetic analysis was based on a two-compartment open model. The average plasma elimination half-life of chlorpheniramine was calculated to be approximately 18.3 hr. The controlled-release products gave a higher Cmax than the 4-mg syrup, but less than two 4-mg tablets. The controlled-release products also extended the time necessary to attain peak drug levels compared to the 4- and 8-mg syrups. The area under the curve (AUC) data for the controlled-release products was not equivalent to equal amounts of the regular-release products. The study indicated that while the controlled-release chlorpheniramine products were successful in prolonging the time course of absorption, this was at the expense of incomplete bioavailability of the drug.
D000293:Adolescent; D000328:Adult; D001682:Biological Availability; D002744:Chlorpheniramine / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D003692:Delayed-Action Preparations; D006801:Humans; D007700:Kinetics; D008297:Male; D013810:Therapeutic Equivalency
D003692:Delayed-Action Preparations; D002744:Chlorpheniramine